Fosaprepitant and Mvasi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Fosaprepitant (fosaprepitant) and Mvasi (bevacizumab-awwb). Common drug interactions include cognitive disorder among females and headache among males.

The phase IV clinical study analyzes what interactions people have when they take Fosaprepitant and Mvasi. It is created by eHealthMe based on reports of 69 people who take the same drugs from the FDA, and is updated regularly.

What is Fosaprepitant?

Fosaprepitant has active ingredients of fosaprepitant. eHealthMe is studying from 1,178 Fosaprepitant users. Check the latest studies of Fosaprepitant.

What is Mvasi?

Mvasi has active ingredients of bevacizumab-awwb. eHealthMe is studying from 3,295 Mvasi users. Check the latest studies of Mvasi.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

69 people who take Fosaprepitant and Mvasi together, and have interactions are studied.

Fosaprepitant and Mvasi drug interactions.

What are the common drug interactions of Fosaprepitant and Mvasi, by gender? *:

female:

Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
Disturbance in attention
Macule (a discoloured spot on the skin)
Nephropathy (damage to or disease of a kidney)
Neutropenia (an abnormally low number of neutrophils)
Night sweats (sweating in night)
Ovarian cancer (cancer of ovary)
Panic reaction
Proteinuria (presence of protein in the urine)
Rectal abscess (pus in rectum)

male:

Headache (pain in head)
Neuropathy peripheral (surface nerve damage)
Aphasia (damage to the parts of the brain that control language)
Feeling hot
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough)
Muscle contractions involuntary (uncontrolled muscle contraction)
Abdominal pain
Decreased appetite
Asthenia (weakness)
Epistaxis (bleed from the nose)

What are the common drug interactions of Fosaprepitant and Mvasi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Arthralgia (joint pain)
Axillary mass
Diarrhoea
Dizziness
Headache (pain in head)
Muscle mass
Aphasia (damage to the parts of the brain that control language)
Muscle contractions involuntary (uncontrolled muscle contraction)
Nausea (feeling of having an urge to vomit)
Odynophagia (painful swallowing, in the mouth (oropharynx) or oesophagus)

30-39:

Headache (pain in head)
Pain in extremity
Pelvic pain
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Abdominal pain
Adenocarcinoma of the cervix (cervical cancer)
Dry throat
Nausea (feeling of having an urge to vomit)
Vaginal discharge
Decreased appetite

40-49:

Neuropathy peripheral (surface nerve damage)
Abdominal pain
Abdominal distension
Abdominal pain upper
Lung carcinoma cell type unspecified stage iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Transaminases increased
Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
General physical health deterioration (weak health status)

50-59:

Neuropathy peripheral (surface nerve damage)
Constipation
Abdominal pain
Anxiety
Ascites (accumulation of fluid in the abdominal cavity)
Epistaxis (bleed from the nose)
Feeling hot
Haematochezia (passage of stools containing blood)
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough)
Hyperhidrosis (abnormally increased sweating)

60+:

Neuropathy peripheral (surface nerve damage)
Nausea (feeling of having an urge to vomit)
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
Weight increased
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
Asthenia (weakness)
Balance disorder
Constipation
Decreased appetite
Mucosal inflammation (infection of mucous membrane)

What are the existing conditions these people have? *

Pain: 12 people, 17.39%
Ovarian Cancer (cancer of ovary): 9 people, 13.04%
Oligodendroglioma (a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell): 7 people, 10.14%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 6 people, 8.70%
Colon Cancer: 6 people, 8.70%
Dizziness: 5 people, 7.25%
Diarrhea: 5 people, 7.25%
Ovarian Cancer Stage Iii: 4 people, 5.80%

* Approximation only. Some reports may have incomplete information.

Do you take Fosaprepitant and Mvasi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously